These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 22765883

  • 1. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
    Zen M, Bassi N, Nalotto L, Canova M, Bettio S, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A.
    Clin Exp Rheumatol; 2012; 30(6):856-63. PubMed ID: 22765883
    [Abstract] [Full Text] [Related]

  • 2. A surge in anti-dsDNA titer predicts a severe lupus flare within six months.
    Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK, Kirou KA.
    Lupus; 2014 Mar; 23(3):293-8. PubMed ID: 24316605
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
    Touma Z, Gladman DD, Ibañez D, Taghavi-Zadeh S, Urowitz MB.
    J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488
    [Abstract] [Full Text] [Related]

  • 7. Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study.
    Peng L, Wang Z, Li M, Wang Y, Xu D, Wang Q, Zhang S, Zhao J, Tian X, Zeng X.
    Clin Rheumatol; 2017 Dec; 36(12):2727-2732. PubMed ID: 28929239
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prolonged clinical remission in patients with systemic lupus erythematosus.
    Steiman AJ, Urowitz MB, Ibañez D, Papneja A, Gladman DD.
    J Rheumatol; 2014 Sep; 41(9):1808-16. PubMed ID: 25086082
    [Abstract] [Full Text] [Related]

  • 10. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A, Magder LS, Barr SG, Petri M.
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [Abstract] [Full Text] [Related]

  • 11. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C, Medina-Rosas J, Santos AM, Jaimes DA, Arbeláez AM, Romero C, Cortes A, Londono J.
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [Abstract] [Full Text] [Related]

  • 12. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J, Shen L, Huq M, Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Hamijoyo L, Luo SF, Wu YJ, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake D, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Navarra SV, Lau CS, Hoi A, Morand EF, Nikpour M, Lateef A, Asia-Pacific Lupus Collaboration.
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Summarizing disease features over time: II. Variability measures of SLEDAI-2K.
    Ibañez D, Gladman D, Urowitz M.
    J Rheumatol; 2007 Feb; 34(2):336-40. PubMed ID: 17183620
    [Abstract] [Full Text] [Related]

  • 17. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, Gatto M, Piantoni S, Nalotto L, Franceschini F, Larosa M, Fredi M, Punzi L, Tincani A, Doria A.
    Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
    [Abstract] [Full Text] [Related]

  • 18. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus.
    Nikpour M, Urowitz MB, Ibañez D, Gladman DD.
    Arthritis Rheum; 2009 Sep 15; 61(9):1152-8. PubMed ID: 19714602
    [Abstract] [Full Text] [Related]

  • 19. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
    Conti F, Ceccarelli F, Perricone C, Miranda F, Truglia S, Massaro L, Pacucci VA, Conti V, Bartosiewicz I, Spinelli FR, Alessandri C, Valesini G.
    PLoS One; 2012 Sep 15; 7(9):e45934. PubMed ID: 23029327
    [Abstract] [Full Text] [Related]

  • 20. International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies.
    Bentow C, Lakos G, Martis P, Wahl E, Garcia M, Viñas O, Espinosa G, Cervera R, Sjöwall C, Carmona-Fernandes D, Santos MJ, Hanly JG, Mahler M.
    Lupus; 2016 Jul 15; 25(8):864-72. PubMed ID: 27252263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.